1. An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants
- Author
-
Chao-bo Lin, Fangzhi Tan, Haopeng Wang, Junzi Ke, Jie Yang, Guisheng Zhong, and Simeng Zhao
- Subjects
Immunogen ,Coronavirus disease 2019 (COVID-19) ,biology ,business.industry ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immune sera ,Virology ,Vaccination ,Pandemic ,biology.protein ,Medicine ,Vector (molecular biology) ,Antibody ,business - Abstract
Prophylactic vaccines against SARS-CoV-2 have been extensively developed globally to overcome the COVID-19 pandemic. However, recently emerging SARS-CoV-2 variants B.1.1.7 and B.1.351 limit the vaccine protection effects and successfully escape antibody cocktail treatment. Herein, based on our previously engineered adeno-associated viral (AAV) vector, AAV-ie, and systematic immunogen screening, we developed an AAV-ie-S1 vaccine with thermostability, high efficiency, safety, and single-dose vaccination advantage. Importantly, the AAV-ie-S1 immune sera efficiently neutralize B.1.1.7 and B.1.351, indicating a potential to circumvent the spreading of SARS-CoV-2.
- Published
- 2021